CardioMEMS Closes $33 Million Series E Financing and Appoints New CFO

ATLANTA--(HSMN NewsFeed)--CardioMEMS, Inc., the pioneer in wireless sensing for the management of chronic cardiovascular diseases such as Heart Failure, today announced the closing of its Series E Preferred Stock financing for $33 million of equity funding led by Arcapita Ventures. Joining Arcapita in this financing round are existing investors Boston Millennia Partners, Medtronic, Inc., Easton Capital Partners, Foundation Medical Partners, and Arboretum Ventures, along with new investors Deerfield Capital Management, Vision Capital Advisors, Aperture Venture Partners and Rockport Venture Securities.
“We are pleased with the continued support of Arcapita Ventures and our existing and new investors,” stated Jay Yadav, MD, Chairman and CEO of CardioMEMS, Inc. "This is a very exciting time for CardioMEMS as we conduct our randomized trial aimed at reducing heart failure hospitalizations with our wireless sensing technology. The absence of leads and batteries in our technology, we believe, provides a substantial safety advantage.”

Full text >>